PCSK9 inhibition: ready for prime time in CKD?
Lowering LDL cholesterol reduces the risk of atherosclerotic vascular disease in a wide range of patients with chronic kidney disease, with no evidence of a threshold below which further reductions no longer reduce risk. Statins safely lower LDL cholesterol, but novel inhibitors of proprotein conver...
| Автори: | , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
Elsevier
2018
|